Recently reported results of a phase 3 study found that patients with psoriatic arthritis (PsA) who received intravenous golimumab (Simponi) had significantly greater improvements in the signs and symptoms of PsA through week 24 than did patients who received placebo.
Anti—tumor necrosis factor (anti-TNF) agents have revolutionized the treatment of patients with psoriatic arthritis (PsA), and have substantially improved clinical outcomes compared to earlier, conventional therapies (such as disease-modifying anti-rheumatic drugs or non-steroidal anti-inflammatory drugs). Recently reported results of a phase 3 study found that patients with PsA who received intravenous golimumab (Simponi), an anti-TNF agent, had significantly greater improvements in the signs and symptoms of PsA through week 24 than did patients who received placebo.
The GO-VIBRANT study, conducted by Arthur Kavanaugh, MD, and colleagues, included patients (n = 480) from 90 sites in 11 countries who were aged 18 years or more, were naïve to biologic therapy, and had active PsA despite conventional therapy. Concomitant methotrexate treatment was allowed. Patients were randomized to receive either intravenous placebo (n = 239) or golimumab at 2 mg per kg (n = 241) at weeks 0, 4, 12, and 20 of the study. The study’s primary endpoint was the proportion of patients meeting the American College of Rheumatology’s 20% improvement criteria (ACR20) at week 14.
The researchers found the following:
The researchers concluded that patients with PsA who were treated with intravenous golimumab experienced significantly greater improvements in disease activity compared with patients receiving placebo, and that the AEs reported in the trial were consistent with the established safety profile of anti-TNF agents. The study will continue through 1 year, when updated results will be presented.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More